WDNA vs. IHE

Last updated Jun 24, 2026

WDNA (WisdomTree BioRevolution Fund) and IHE (iShares U.S. Pharmaceuticals ETF) are both Health & Biotech Equities funds - WDNA tracks the WisdomTree BioRevolution Index while IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index. Both are passively managed. Over the past 5 years, WDNA returned -5.03%/yr vs 10.55%/yr for IHE. A 0.63 correlation means they provide meaningful diversification when combined. WDNA charges 0.45%/yr vs 0.42%/yr for IHE.

Performance

WDNA vs. IHE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WisdomTree BioRevolution Fund (WDNA) and iShares U.S. Pharmaceuticals ETF (IHE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, WDNA achieves a 13.32% return, which is significantly higher than IHE's 11.65% return.

WDNA

• 1D: 0.49%
• 1M: 8.93%
• YTD: 13.32%
• 6M: 11.11%
• 1Y: 50.90%
• 3Y*: 5.47%
• 5Y*: -5.03%
• 10Y*: —

IHE

• 1D: 1.60%
• 1M: 3.16%
• YTD: 11.65%
• 6M: 10.97%
• 1Y: 46.87%
• 3Y*: 18.43%
• 5Y*: 10.55%
• 10Y*: 8.99%

*Multi-year figures are annualized to reflect compound growth (CAGR)

WDNA vs. IHE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
WDNA WisdomTree BioRevolution Fund	13.32%	22.68%	-14.18%	-2.07%	-26.29%	-4.92%
IHE iShares U.S. Pharmaceuticals ETF	11.65%	31.69%	8.13%	1.06%	-4.87%	10.78%

Correlation

The correlation between WDNA and IHE is 0.66, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.66
Correlation (3Y) Calculated over the trailing 3-year period	0.60
Correlation (5Y) Calculated over the trailing 5-year period	0.63
Correlation (All Time) Calculated using the full available price history since Jun 3, 2021	0.63

The correlation between WDNA and IHE has been stable across timeframes, ranging from 0.60 to 0.66 - a consistent structural relationship.

WDNA vs. IHE - Sectors Allocation Comparison

Sectors	WDNA	IHE
Healthcare	85.0%	100.0%
Basic Materials	6.5%	-
Consumer Defensive	3.0%	-
Energy	1.1%	-
Communication Services	-	-
Consumer Cyclical	-	-
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

WDNA vs. IHE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WDNA

WDNA Risk / Return Rank: 66
WDNA Sharpe Ratio Rank: 65
WDNA Sortino Ratio Rank: 66
WDNA Omega Ratio Rank: 56
WDNA Calmar Ratio Rank: 85
WDNA Martin Ratio Rank: 59

IHE

IHE Risk / Return Rank: 87
IHE Sharpe Ratio Rank: 88
IHE Sortino Ratio Rank: 90
IHE Omega Ratio Rank: 82
IHE Calmar Ratio Rank: 91
IHE Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WDNA vs. IHE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and iShares U.S. Pharmaceuticals ETF (IHE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	WDNA	IHE	Difference
Sharpe ratio: Return per unit of total volatility	1.98	2.74	-0.76
Sortino ratio: Return per unit of downside risk	2.81	3.95	-1.14
Omega ratio: Gain probability vs. loss probability	1.32	1.46	-0.14
Calmar ratio: Return relative to maximum drawdown	4.37	5.56	-1.19
Martin ratio: Return relative to average drawdown	9.80	17.09	-7.29

WDNA vs. IHE - Sharpe Ratio Comparison

The current WDNA Sharpe Ratio is 1.98, which is comparable to the IHE Sharpe Ratio of 2.74. The chart below compares the historical Sharpe Ratios of WDNA and IHE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

WDNA vs. IHE - Drawdown Comparison

The maximum WDNA drawdown since its inception was -58.87%, which is greater than IHE's maximum drawdown of -38.20%. Use the drawdown chart below to compare losses from any high point for WDNA and IHE.

Drawdown Indicators

	WDNA	IHE	Difference
Max Drawdown Largest peak-to-trough decline	-58.87%	-38.20%	-20.67%
Max Drawdown (1Y) Largest decline over 1 year	-11.70%	-8.47%	-3.23%
Max Drawdown (3Y) Largest decline over 3 years	-38.25%	-15.92%	-22.33%
Max Drawdown (5Y) Largest decline over 5 years	-58.87%	-16.03%	-42.84%
Max Drawdown (10Y) Largest decline over 10 years	—	-29.59%	—
Current Drawdown Current decline from peak	-27.05%	-0.70%	-26.35%
Average Drawdown Average peak-to-trough decline	-35.56%	-7.90%	-27.66%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.21%	2.75%	+2.46%

Volatility

WDNA vs. IHE - Volatility Comparison

WisdomTree BioRevolution Fund (WDNA) has a higher volatility of 7.39% compared to iShares U.S. Pharmaceuticals ETF (IHE) at 5.27%. This indicates that WDNA's price experiences larger fluctuations and is considered to be riskier than IHE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	WDNA	IHE	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.39%	5.27%	+2.12%
Volatility (6M) Calculated over the trailing 6-month period	16.98%	12.68%	+4.30%
Volatility (1Y) Calculated over the trailing 1-year period	25.90%	17.22%	+8.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.14%	16.28%	+8.86%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.06%	18.05%	+7.01%

WDNA vs. IHE - Expense Ratio Comparison

WDNA has a 0.45% expense ratio, which is higher than IHE's 0.42% expense ratio.

Dividends

WDNA vs. IHE - Dividend Comparison

WDNA's dividend yield for the trailing twelve months is around 4.03%, more than IHE's 1.56% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
IHE iShares U.S. Pharmaceuticals ETF	1.56%	1.76%	1.73%	1.39%	2.01%	1.49%	1.19%	1.40%	1.25%	1.36%	0.92%	1.93%
WDNA WisdomTree BioRevolution Fund	4.03%	4.57%	0.75%	0.80%	0.38%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both WDNA and IHE in my portfolio?

WDNA and IHE have a correlation of 0.66, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, WDNA or IHE?

WDNA has higher volatility (7.39%) compared to IHE (5.27%). In terms of maximum drawdown, WDNA dropped -58.87% vs IHE's -38.20%.

Which ETF is better, WDNA or IHE?

On 5-year performance, IHE leads with 10.55% vs -5.03% for WDNA. On fees, IHE is cheaper at 0.42% per year. On volatility, IHE has been the lower-risk option at 5.27%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, WDNA or IHE?

Over the 5-year period, IHE has performed better with a 10.55% return vs -5.03%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, WDNA or IHE?

IHE is cheaper with a 0.42% expense ratio, compared with 0.45% for WDNA.

Which ETF pays a higher dividend yield, WDNA or IHE?

WDNA has the higher dividend yield at 4.03%, compared with 1.56% for IHE.

What is the main difference between WDNA and IHE?

WDNA tracks WisdomTree BioRevolution Index, while IHE tracks Dow Jones U.S. Select Pharmaceuticals Index. They also come from different issuers: WisdomTree and iShares. Their fees differ too: 0.45% for WDNA and 0.42% for IHE.

Which has better risk-adjusted returns?

IHE currently has the higher Sharpe Ratio (2.74 vs 1.98), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.